Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 4/20 | 0.54 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.53 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.50 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.50 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.50 |
| ▸ | PRF1 | P14222 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | FABP4 | P15090 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2158043 | 0.81 | SLC22A12 (0.55) | SLC22A12HSD17B1HSD17B2 | |
| SCHEMBL2157999 | 0.79 | PTK2B (0.47) | ALPLBRD4ACLY | |
| SCHEMBL2158492 | 0.77 | USP2 (0.49) | PRF1BRD4FABP4FABP5 | |
| SCHEMBL2157872 | 0.75 | ALPL (0.55) | ALPLACLY | |
| SCHEMBL2246911 | 0.75 | IKBKB (0.52) | HSD17B1HSD17B2SLC40A1ACLY | |
| SCHEMBL2158433 | 0.75 | RXFP1 (0.48) | ALPLBRD4FABP4FABP5 | |
| SCHEMBL7570846 | 0.75 | SLC22A12 (0.62) | ALPLSLC22A12HSD17B1HSD17B2SLC40A1 | |
| SCHEMBL2158054 | 0.74 | ALDH1A1 (0.52) | IDH1 | |
| SCHEMBL2158687 | 0.74 | CNR1 (0.42) | BRD4ACLY | |
| SCHEMBL2158080 | 0.74 | CNR1 (0.42) | SLC22A12HSD17B1HSD17B2FABP4FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985769-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-26 | — | — | US | disclosed |
| US-20060142347-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2006-06-29 | — | — | US | disclosed |
| US-6881741-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142347-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | HAVCR2, ZC3HAV1, MAVS | ALPL 4636/4885SLC22A12 2078/4885HSD17B1 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.